Susan Altschuller
Financieel Directeur/CFO bij CEREVEL THERAPEUTICS HOLDINGS, INC.
Vermogen: 711 530 $ op 30-04-2024
Profiel
Susan Altschuller is currently the Director at Vestaron Corp.
She also holds current positions as an Independent Director at Mural Oncology Plc, Chief Financial Officer at Cerevel Therapeutics Holdings, Inc., and Chief Financial Officer at Cerevel Therapeutics, Inc. Additionally, she is a Founding Member of the HNRNP Family Foundation.
In her former roles, Dr. Altschuller served as the Chief Financial Officer & Senior Vice President at ImmunoGen, Inc. from 2020 to 2022.
She was also the Head-Investor Relations at Biogen, Inc., Head-Enterprise Finance at Alexion Pharmaceuticals, Inc., and Head-Investor Relations at Bioverativ, Inc.Dr. Altschuller's education includes a doctorate from the Illinois Institute of Technology, an undergraduate degree from Tulane University (Louisiana), and an MBA from the MIT Sloan School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2024 | 16 913 ( 0.01% ) | 711 530 $ | 30-04-2024 | |
-.--% | 30-05-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Susan Altschuller
| Bedrijven | Functie | Begin |
|---|---|---|
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Financieel Directeur/CFO | 15-05-2023 |
Vestaron Corp.
 Vestaron Corp. Chemicals: SpecialtyProcess Industries Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC. | Directeur/Bestuurslid | - |
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Financieel Directeur/CFO | 01-05-2023 |
Eerdere bekende functies van Susan Altschuller
| Bedrijven | Functie | Einde |
|---|---|---|
| IMMUNOGEN, INC. | Financieel Directeur/CFO | 23-12-2022 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 01-04-2020 |
| BIOVERATIV INC | Public Communications Contact | 01-01-2018 |
| BIOGEN INC. | Investor Relations Contact | - |
Opleiding van Susan Altschuller
| Tulane University (Louisiana) | Undergraduate Degree |
| Illinois Institute of Technology | Doctorate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Vestaron Corp.
Vestaron Corp. Chemicals: SpecialtyProcess Industries Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC. | Process Industries |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Health Technology |
